Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions

30 Apr 2018

Abstract excerpt

Human cytomegalovirus (HCMV) is the most common congenital infection worldwide, frequently causing hearing loss and brain damage in afflicted infants. A vaccine to prevent maternal acquisition of HCMV during pregnancy is necessary to reduce the incidence of infant disease. The glycoprotein B (gB) + MF59 adjuvant subunit vaccine platform is the most successful HCMV vaccine tested to date, demonstrating ∼50%...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytomegalovirus and herpesvirus research
Share to Herpesvirus Infections and Treatments
Share to Polyomavirus and related diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29712861
DOI: 10.1073/pnas.1800177115

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functionsPMID 29712861Read ↗

HCMV glycoprotein B subunit vaccine efficacy was mediated by non-neutralizing antibody effector functionsSemantic proximity Read ↗

Specificity and effector functions of non-neutralizing gB-specific monoclonal antibodies isolated from healthy individuals with human cytomegalovirus infectionSemantic proximity Read ↗

Antibody binding to native cytomegalovirus glycoprotein B predicts efficacy of the gB/MF59 vaccine in humansSemantic proximity Read ↗

Human Cytomegalovirus mRNA-1647 Vaccine Candidate Elicits Potent and Broad Neutralization and Higher Antibody-Dependent Cellular Cytotoxicity Responses Than the gB/MF59 VaccineSemantic proximity Read ↗

Genetic signatures of human cytomegalovirus variants acquired by seronegative glycoprotein B vaccineesSemantic proximity Read ↗

Multivalent cytomegalovirus glycoprotein B nucleoside modified mRNA vaccines did not demonstrate a greater antibody breadthSemantic proximity Read ↗

Multivalent Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccines Demonstrate a Greater Breadth in T cell but not Antibody ResponsesSemantic proximity Read ↗

Multivalent Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccines Demonstrate a Greater Breadth in T cell but not Antibody ResponsesSemantic proximity Read ↗

Vaccination with a disabled infectious single cycle cytomegalovirus vaccine elicits a distinct glycoprotein B-specific monoclonal antibody repertoire compared to that of naturally-infected individualsSemantic proximity Read ↗

Human Cytomegalovirus Vaccine Based on the Envelope gH/gL Pentamer ComplexSemantic proximity Read ↗

Limited Effector Memory B-Cell Response to Envelope Glycoprotein B During Primary Human Cytomegalovirus Infection.Semantic proximity Read ↗

Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.